nimotuzumab
biocon,daiichi sankyo,oncoscience
['nimotuzumab', 'pancreatic']
news from #asco22 - nimotuzumab gemcitabine prolongs survival in patients with kras wild-type #pancreaticcancer read more from the randomized phase 3 notable study here: #oncology 
The content you need, when you need it.